What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.36%
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
18.0%Sustainable
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.04BCNY
752.32M · vs all stocks (USD)
Updated Sep 21, 2026
Trailing P/E
49.72x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Revenue (TTM)
10.76BCNY
1.61B · vs all stocks (USD)
Updated Sep 21, 2026
Profit Margin
0.96%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Beta
0.4260x
vs all stocks
Updated Sep 21, 2026
52-Week Change
16.08%
vs all stocks
Updated Sep 21, 2026
Forward Annual Dividend Yield
0.36%
vs all stocks
Updated Sep 21, 2026
Market Capitalization
5.04BCNY
752.32M · vs all stocks (USD)
Updated Sep 21, 2026
Enterprise Value
7.02BCNY
1.05B · vs all stocks (USD)
Updated Sep 21, 2026
Trailing P/E
49.72x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Price to Sales (TTM)
0.4686x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Price to Book (MRQ)
2.52x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Enterprise to Revenue
0.6520x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Enterprise to EBITDA
26.27x
vs Pharmaceutical Retailers peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 27.78×.Updated Sep 21, 2026
Gross Margin
26.93%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Profit Margin
0.96%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Operating Margin
2.67%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Return on Assets (TTM)
1.38%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Return on Equity (TTM)
5.15%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Revenue (TTM)
10.76BCNY
1.61B · vs all stocks (USD)
Updated Sep 21, 2026
Revenue per Share (TTM)
25.54CNYUpdated Sep 21, 2026
Quarterly Revenue Growth
8.40%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Gross Profit (TTM)
2.81BCNY
419.94M · vs all stocks (USD)
Updated Sep 21, 2026
EBITDA (TTM)
252.65MCNY
37.70M · vs all stocks (USD)
Updated Sep 21, 2026
Net Income (TTM)
103.76MCNY
15.48M · vs all stocks (USD)
Updated Sep 21, 2026
Quarterly Earnings Growth (YoY)
45.10%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Operating Cash Flow (TTM)
708.76MCNY
105.76M · vs all stocks (USD)
Updated Sep 21, 2026
Levered Free Cash Flow (TTM)
810.58MCNY
120.96M · vs all stocks (USD)
Updated Sep 21, 2026
Forward Annual Dividend Rate
0.0500CNYUpdated Sep 21, 2026
Forward Annual Dividend Yield
0.36%
vs all stocks
Updated Sep 21, 2026
Trailing Annual Dividend Rate
0.0450CNYUpdated Sep 21, 2026
Trailing Annual Dividend Yield
0.37%
vs all stocks
Updated Sep 21, 2026
Payout Ratio
18.00%
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Minority Interest (Equity)
162.55MCNYFY2025 · Dec 31, 2025
Revenue
10.33BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
7.63BCNYFY2025 · Dec 31, 2025
Gross Profit
2.70BCNYFY2025 · Dec 31, 2025
Operating Income
223.90MCNY
33.41M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
171.73MCNYFY2025 · Dec 31, 2025
Income Tax Expense
54.82MCNYFY2025 · Dec 31, 2025
Net Income
116.91MCNYFY2025 · Dec 31, 2025
EBIT
298.64MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
615.18MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
385.85MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
58.75MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
10.24MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
126.91MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.2800CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.2800CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
407.97MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
407.97MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
116.91MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-2.68MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
191.94MCNYFY2025 · Dec 31, 2025
Free Cash Flow
20.31MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
395.22MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
116.91MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
148.88MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-219.04MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
145.19MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-171.63MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-460.32MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-14.29MCNYFY2025 · Dec 31, 2025
Sale of Investments
26.77MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-34.88MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-654.35MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
1.31BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-1.75BCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-90.27MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-32.48MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-559.02MCNYFY2025 · Dec 31, 2025
Shares Outstanding
405.61MSharesUpdated Sep 21, 2026
Float Shares
109.61MSharesUpdated Sep 21, 2026
% Held by Insiders
74.96%
vs all stocks
Updated Sep 21, 2026
% Held by Institutions
0.08%
vs all stocks
Updated Sep 21, 2026
Total Cash (MRQ)
1.46BCNY
218.34M · vs all stocks (USD)
Updated Sep 21, 2026
Total Cash per Share (MRQ)
3.61CNYUpdated Sep 21, 2026
Total Debt (MRQ)
3.29BCNY
491.65M · vs all stocks (USD)
Updated Sep 21, 2026
Total Debt to Equity (MRQ)
1.46x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Current Ratio (MRQ)
0.8930x
vs Pharmaceutical Retailers peers
Updated Sep 21, 2026
Book Value per Share (MRQ)
4.93CNYUpdated Sep 21, 2026
Total Assets
9.41BCNY
1.40B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
5.02BCNYFY2025 · Dec 31, 2025
Total Liabilities
7.11BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
4.39BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.57BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
5.55BCNYFY2025 · Dec 31, 2025
Cash
395.22MCNYFY2025 · Dec 31, 2025
Cash Equivalents
845.38MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.24BCNYFY2025 · Dec 31, 2025
Accounts Receivable
1.06BCNYFY2025 · Dec 31, 2025
Inventory
1.89BCNYFY2025 · Dec 31, 2025
Accounts Payable
3.15BCNYFY2025 · Dec 31, 2025
Short-term Debt
1.63BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
270.88MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.44BCNYFY2025 · Dec 31, 2025
Common Stock (Book)
405.36MCNYFY2025 · Dec 31, 2025
Retained Earnings
738.64MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.29BCNY
342.23M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
10.52CNYUpdated Sep 21, 2026
52-Week High
23.01CNYUpdated Sep 21, 2026
52-Week Change
16.08%
vs all stocks
Updated Sep 21, 2026
Beta
0.4260x
vs all stocks
Updated Sep 21, 2026
50-Day MA
13.11CNYUpdated Sep 21, 2026
200-Day MA
14.48CNYUpdated Sep 21, 2026
Avg 10-Day Volume
4.22MSharesUpdated Sep 21, 2026
Avg 30-Day Volume
7.22MSharesUpdated Sep 21, 2026
Diluted EPS (TTM)
0.2500CNYUpdated Sep 21, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 49.72×, higher than 95% of its Pharmaceutical Retailers peers (median 18.97×)Significant